Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis

Archives of Internal Medicine

Volumn 168, Issue 17, 2008, Pages 1927-1928

  Gaffo, Angelo L ^b   Alarcón, Graciela S ^a  

^a University of Alabama at Birmingham   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

CLINICAL FEATURE; DISEASE COURSE; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG FIBROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; LUNG DISEASES, INTERSTITIAL; METHOTREXATE;

EID: 52649180598     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.17.1927     Document Type: Letter

References (5)

1. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159-166.
2. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extraarticular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722-727.
3. Cimmino MA, Salvarani C, Macchioni P, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000;19(6):213-217.
4. Alarcón GS, Kremer JM, Macaluso M, et al; Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med. 1997;127(5):356-364.
5. Carroll GJ, Thomas R, Phatourus CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994;21(1):51-54.